Buprenorphine and Naloxone Sublingual Tablets recall: Impurity Out of Spec
Buprenorphine and Naloxone Sublingual Tablets, 2 mg/0.5 mg 30 tablets per bottle, Rx only, Distributed by: Teva Pharmaceuticals USA, Inc., North Wales, PA 19454, NDC 0093-5720-56
Why was Buprenorphine and Naloxone Sublingual Tablets recalled?
Failed Impurities/Degradation Specifications: out of specification test results for related compounds largest unknown impurity.
What should I do if I have this product?
Review the official FDA enforcement record for current instructions.
What to do with a recalled product: refunds, receipts, safe disposal and how to report a problem.
Is my product affected?
Compare the item in your hand with every identifier below from the official FDA record. Only products that match the listed product and lot, UPC or model codes are part of this recall.
Which lot codes, UPCs or models are affected?
Lot #: 30227613A, 30227614A, 30227615A, EXP 6/2017; 30228559A, 30228560A, EXP 9/2017; 3000123, EXP 7/2018
- Product
- Buprenorphine and Naloxone Sublingual Tablets, 2 mg/0.5 mg 30 tablets per bottle, Rx only, Distributed by: Teva Pharmaceuticals USA, Inc., North Wales, PA 19454, NDC 0093-5720-56
- Recalling firm
- Teva Pharmaceuticals USA
- Quantity
- 25264 bottles
- Distribution
- Nationwide in the USA
- Recall date
- July 26, 2017
- Classification
- Class III
- Status
- Terminated
- Agency
- FDA (drug)